Previous 10 | Next 10 |
2023-05-10 17:23:02 ET Aravive press release ( NASDAQ: ARAV ): Q1 GAAP EPS of -$0.66 misses by $0.34 . Revenue of $1.49M (+36.7% Y/Y) beats by $1.07M . For further details see: Aravive GAAP EPS of -$0.66 misses by $0.34, revenue of $1.49M beats by $1.07M
On Track for PROC Pivotal Phase 3 Trial Readout Mid-2023 Promising ccRCC Phase 1b/2 Results to Date; Update to be Presented at ASCO 2023 Strengthened Management Team with Appointment of Carolina Petrini as Chief Commercial Officer Company hosting Key Opinion Le...
HOUSTON, May 08, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced it will host a virtual Key Opinion Leader (KOL) event on its late-stage on...
HOUSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of a poster featuring batiraxcept data in clear cell re...
HOUSTON, April 11, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the appointment of Carolina Petrini as the Company’s new Chief Co...
HOUSTON, March 15, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today reported fourth quarter and full year ended December 31, 2022 financial results an...
The U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) to Aravive's ( NASDAQ: ARAV ) batiraxcept to treat pancreatic ductal adenocarcinoma cancer (PDAC). PDAC is a type of cancer that forms in the pancreas and starts in the cells that line the ducts which ca...
Dose escalation portion of ongoing Phase 1b/2 pancreatic adenocarcinoma trial initiated, with preliminary results expected in 2H 2023 HOUSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing ...
Summary Two new Breakout Stocks for Week 9 with better than 10% short-term upside and a Dow 30 Pick. Average cumulative returns for 2023 are +35.8% YTD. This week, the Momentum Gauges® turned negative for the first time in 2023 with an early negative test signal Feb. 3rd warning of...
If you’re looking for penny stocks to buy, you might want to get a second opinion. You could go to places like Fintwit or Reddit to discover what the mom-and-pop investors are speculating on. Another way to see varying perceptions of companies is to find out what analysts think. Using ...
News, Short Squeeze, Breakout and More Instantly...
Amerityre Corp (AMTY) is expected to report for Q3 2024 CURO Group Holdings Corp. (CUROQ) is expected to report for Q1 2024 China Health Industries Holdings Inc (CHHE) is expected to report for Q3 2024 Avid Bioservices Inc. (CDMO) is expected to report $0.03 for Q4 2024 Anterix In...
Blue Ridge Real Estate Co. (BRRE) is expected to report for Q2 2024 Aravive Inc. (ARAV) is expected to report for Q1 2024 Biocept Inc. (BIOCQ) is expected to report for Q1 2024 Golden Matrix Group Inc. (GMGI) is expected to report for Q2 2024 Bluejay Diagnostics Inc. (BJDX) is exp...
SunPower Corporation (SPWR) is expected to report $-0.29 for Q1 2024 Siemens Healthineers AG ADR (SMMNY) is expected to report for Q2 2024 Specificity Inc Com (SPTY) is expected to report for Q1 2024 Tokyo Gas Co. Ltd. ADR (TKGSY) is expected to report for Q4 2024 Gol Linhas Aerea...